Company / R&D Expense
Alaunos Therapeutics, Inc. R&D Expense History
FY2012-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$362.0K
FY2025
5-year range
$362.0K / $52.7M
FY2021-FY2025
Trend
-97.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has declined for 4 consecutive years, from $53M in FY2021 to $362,000 in FY2025.
Based on SEC 10-K filings.
$362,000 in FY2025 with a 5-year CAGR of -59.7%.
Declined from $25M to $362,000 over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -80.6%
- 5-Year CAGR
- -59.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- Alaunos Therapeutics, Inc.'s r&d expense has declined for 4 consecutive years.
- 5-year CAGR of -59.7%, indicating a declining trend.
- In FY2025, r&d expense decreased 97.8% year-over-year.
- Peak r&d expense was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score -3.79 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $362.0K | -97.8% |
| FY2024 | $16.3M | -34.9% |
| FY2023 | $25.0M | -49.6% |
| FY2022 | $49.6M | -5.8% |
| FY2021 | $52.7M | +54.4% |
| FY2020 | $34.1M | -24.3% |
| FY2019 | $45.1M | -71.4% |
| FY2018 | $157.8M | +801.7% |
| FY2013 | $17.5M | +35.6% |
| FY2012 | $12.9M | +183.4% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026